Applied Molecular Transport (AMTI) Stock Price, News & Analysis

Company Overview

Applied Molecular Transport Inc., a clinical-stage biopharmaceutical company, engages in the design and development of a pipeline of oral biologic product candidates to treat autoimmune, inflammatory, metabolic, and other diseases. The company's lead product candidate is AMT-101, a gastrointestinal (GI) selective oral fusion of rhIL-10 that is in Phase II clinical trials to treat patients with chronic pouchitis, as well as is in Phase II development to treat patients with rheumatoid arthritis. It develops AMT-126, a GI-selective oral fusion of interleukin 22, which is in a Phase I clinical trial for diseases related to intestinal epithelium barrier function defects. The company, through its technology platform, designs and develops various oral and respiratory biologic therapeutic modalities, such as peptides, proteins, antibodies, antibody fragments, and ribonucleic acid therapeutics. Applied Molecular Transport Inc. was founded in 2010 and is headquartered in South San Francisco, California. As of December 27, 2023, Applied Molecular Transport Inc. operates as a subsidiary of Cyclo Therapeutics, Inc.

Key Stats

• Today's Range: $0.26 to $0.26
• 50-Day Range: $0.16 to $0.31
• 52-Week Range: $0.13 to $0.84
• Volume: N/A
• Average Volume: 470,969 shs
• Market Capitalization: $10.87 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

AMTI Stock Analysis - Frequently Asked Questions

How were Applied Molecular Transport's earnings last quarter?

Applied Molecular Transport Inc. (NASDAQ:AMTI) posted its quarterly earnings results on Wednesday, November, 10th. The company reported ($0.68) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.62) by $0.06.

When did Applied Molecular Transport IPO?

Applied Molecular Transport (AMTI) raised $130 million in an initial public offering (IPO) on Friday, June 5th 2020. The company issued 10,000,000 shares at a price of $12.00-$14.00 per share. BofA Securities, Jefferies and SVB Leerink served as the underwriters for the IPO.

What other stocks do shareholders of Applied Molecular Transport own?

Based on aggregate information from My MarketBeat watchlists, some other companies that Applied Molecular Transport investors own include Meta Platforms (META), BioLife Solutions (BLFS), Micron Technology (MU), Advanced Micro Devices (AMD), Athenex (ATNX), Bristol-Myers Squibb (BMY) and Alibaba Group (BABA).

Company Calendar

• Last Earnings: 11/10/2021
• Today: 4/02/2025
• Fiscal Year End: 12/31/2025

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Current Symbol: NASDAQ:AMTI
• CIK: 1801777
• Web: www.appliedmt.com
• Phone: 650-392-0420
• Fax: N/A
• Employees: 13
• Year Founded: N/A

Profitability

• EPS (Most Recent Fiscal Year): ($1.90)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: $-126,320,000.00
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -223.46%
• Return on Assets: -126.91%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 4.99
• Quick Ratio: 4.99

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.56 per share
• Price / Book: 0.17

Miscellaneous

• Outstanding Shares: 41,337,000
• Free Float: 34,764,000
• Market Cap: $10.87 million
• Optionable: Optionable
• Beta: 2.28